oxonic acid has been researched along with Benign Neoplasms in 55 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pharmacokinetic parameters, including Cmax, Tmax, t1/2, AUC0-t, and AUC0-∞ were determined using non-compartmental models with DAS2." | 2.78 | Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients. ( Bian, HH; Chen, L; Pu, WY; Wang, H; Wang, J; Zhang, H; Zhu, H; Zhu, MG; Zhuang, ZX, 2013) |
| " To increase the bioavailability of S-1, the administration of S-1 under fasting condition was more effective in the western countries." | 2.77 | Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. ( Hilger, RA; Mende, B; Saito, K; Scheulen, ME; Strumberg, D; Zergebel, C, 2012) |
| "The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone." | 2.76 | A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. ( Mendelson, DS; Ravage-Mass, L; Rosen, LS; Saif, MW; Saito, K; Zergebel, C, 2011) |
| "S-1, oxaliplatin and bevacizumab can be administered with acceptable safety and tolerability and without evidence of pharmacokinetic interactions." | 2.76 | Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. ( Chung, KY; Hollywood, E; Saito, K; Saltz, LB; Segal, M; Zergebel, C, 2011) |
| "We developed a population pharmacokinetic (PPK) model of S-1 including the cytochrome P450 (CYP) 2A6 genotype and then used this PPK model to assess the influence of the CYP2A6 genotype on PK parameters of S-1 and the relationship between toxicity and the individual maximum concentrations (Cmax) or the area under the concentration-time curve (AUC) of 5-fluorouracil (5-FU) in Japanese patients with advanced cancer." | 2.75 | Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. ( Adachi, M; Fujita, K; Hirose, T; Ishida, H; Miwa, K; Mizuno, K; Nagashima, F; Nishimura, K; Sasaki, Y; Sunakawa, Y; Tanigawara, Y; Yamashita, K, 2010) |
| "S-1 is an oral anticancer agent that combines tegafur (FT) with 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate." | 2.74 | Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas. ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Kawara, K; Kodama, K; Miwa, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W, 2009) |
| " Thus, we prospectively analyzed the effects of the CYP2A6 genotype, plasma level of CDHP, and patient characteristics on the pharmacokinetic (PK) variability of FT and 5-FU." | 2.73 | CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Endo, S; Fujita, K; Ichikawa, W; Kamataki, T; Kawara, K; Kodama, K; Miwa, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W, 2008) |
| " Fasting decreased Tmax of FT, 5FU, CDHP, and oxonic acid significantly (P < 0." | 2.71 | The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. ( Beijnen, JH; Fumoleau, P; Giaccone, G; Holwerda, U; Noordhuis, P; Peters, GJ; Schellens, JH; Schornagel, JH; Schrijvers, A; Van Groeningen, CJ; Voorn, D, 2004) |
| " Pharmacokinetic data are consistent with potent modulation of 5-fluorouracil (5-FU) by CDHP, with prolonged half-life and 5-FU AUC at least 10-fold higher than reported in previous studies of equitoxic doses of tegafur modulated by uracil." | 2.70 | Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. ( Beard, M; Cohen, SJ; Damle, B; DeCillis, AP; Leichman, CG; Letrent, SP; Meropol, NJ; Proefrock, A; Roedig, B; Yeslow, G, 2002) |
| " Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128." | 2.69 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. ( Aiba, K; Denno, R; Hirata, K; Horikoshi, N; Ishizuka, H; Nakano, Y; Okazaki, M; Sasaki, K; Shirasaka, T; Taguchi, T; Uno, S; Yamada, Y, 1999) |
| "Phase II trials are warranted in tumors known to be responsive to 5-FU treatment." | 2.69 | Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. ( de Vries, MJ; Gall, H; Giaccone, G; Hanauske, AR; Noordhuis, P; Peters, GJ; Pinedo, HM; Schornagel, JH; Swart, MS; Turner, SL; van Groeningen, CJ, 2000) |
| " However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients." | 2.50 | Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'. ( Fujita, K; Sasaki, Y, 2014) |
| "5-FU is a core anticancer agent for GI and other malignancies, and infusional 5-FU regimens have been widely utilized." | 2.48 | S-1 as a core anticancer fluoropyrimidine agent. ( Miura, K; Sasaki, I; Shirasaka, T; Yamaue, H, 2012) |
| "Lentinan is a beta(1-3) glucan clarified to have a life prolonging effect in non-operable, recurrent gastric cancer patients in combination with chemotherapy." | 2.43 | [Anticancer immunotherapy with perorally effective lentinan]. ( Hamuro, J, 2005) |
| " When WF is combined with S-1, the prothrombin time-international normalized ratio (PT-INR) and dose adjustment of WF should be closely monitored." | 1.43 | [Evaluation of Drug Interaction between S-1 and Warfarin]. ( Fuse, N; Ikegawa, K; Nomura, H; Saito, S; Suzuki, S; Yamamoto, K, 2016) |
| "Accurate glomerular filtration rate (GFR) evaluation is significant for drug dosing of carboplatin, anticancer drug excreted mainly from kidney." | 1.42 | Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1. ( Ando, Y; Hayashi, M; Kamiya, H; Kobayashi, R; Maruyama, S; Matsuo, S; Nakao, M; Shibata, K; Shimokata, T; Teramachi, H; Tsuchiya, T; Yasuda, Y, 2015) |
| "S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0." | 1.36 | Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? ( Asai, S; Ishii, Y; Suzuki, S; Takahashi, Y; Takayama, T, 2010) |
| "When epiphora is observed in patients on S-1 therapy, it is necessary to assess optic disorders by an opthalmologist immediately because of suspicion of injury to the cornea and lacrimal duct." | 1.36 | [Optic lesions in patients with epiphora during S-1 therapy]. ( Atsumi, H; Kuze, S; Kyokane, T; Nakamura, H; Shibahara, H; Takamizawa, J, 2010) |
| " Furthermore, 'alternate-day S-1 regimen' may improve the dosing schedule for 5-FU by utilizing its strongly time-dependent mode of action; the former is characterized by the low incidences of myelotoxicity and non-hematologic toxicities (e." | 1.35 | Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. ( Shirasaka, T, 2009) |
| " It was suggested that adverse effects might be alleviated by suppressing acid secretion in the stomach in the post-gastrectomy group." | 1.35 | [Discussion of alleviating digestive medication toxicity in S-1 administered patients--retrospective and comparative study of the health records of continuously-administered patients and withdrawal patients]. ( Fujii, H; Nakao, K, 2009) |
| "Although it is recommended that the standard S-1 dosage should be based on how large the body surface area is, an on-site setting of the appropriate dosage is often lower than the standard one, depending on the individual's condition and considering possible side effects and so, on." | 1.35 | [Determining S-1 dosage at hospitals prioritizing cancer chemotherapy]. ( Anami, S; Furukawa, H; Hasegawa, K; Imamura, H; Kitada, N; Miyabe, T; Morimoto, S; Morita, S; Tabuse, K; Watari, M; Yamasaki, H, 2008) |
| " As a single agent, S-1 showed higher antitumor activity with its low intestinal toxicity compared to continuous venous infusion 5-FU, the most effective dosing method of 5-FU, and/or to clinically available oral fluoropyrimidines such as UFT, doxyfluridine and capecitabine on various murine tumors and human tumor xenografts." | 1.33 | [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. ( Fukushima, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (9.09) | 18.2507 |
| 2000's | 20 (36.36) | 29.6817 |
| 2010's | 29 (52.73) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Takeuchi, M | 1 |
| Imamura, CK | 1 |
| Booka, E | 1 |
| Takeuchi, H | 1 |
| Mizukami, T | 1 |
| Kawakami, T | 1 |
| Funakoshi, T | 1 |
| Wakuda, K | 1 |
| Aoki, Y | 1 |
| Hamamoto, Y | 1 |
| Kitago, M | 1 |
| Kawakubo, H | 1 |
| Boku, N | 1 |
| Tanigawara, Y | 2 |
| Kitagawa, Y | 1 |
| Moriya, K | 1 |
| Shimizu, H | 1 |
| Handa, S | 1 |
| Sasaki, T | 2 |
| Sasaki, Y | 5 |
| Takahashi, H | 1 |
| Nakamura, S | 1 |
| Yoshida, H | 1 |
| Kato, Y | 1 |
| Okuda, Y | 1 |
| Mikame, Y | 1 |
| Watano, R | 1 |
| Masubuchi, M | 1 |
| Nishijima, H | 1 |
| Shinada, M | 1 |
| Mori, M | 1 |
| Fujii, H | 2 |
| Sudoh, T | 1 |
| Akune, Y | 1 |
| Yamada, M | 1 |
| Shigeyasu, C | 1 |
| Milano, G | 1 |
| Fujita, K | 4 |
| Kase, S | 1 |
| Shibata, K | 1 |
| Yasuda, Y | 1 |
| Kobayashi, R | 1 |
| Ando, Y | 3 |
| Shimokata, T | 1 |
| Kamiya, H | 1 |
| Hayashi, M | 1 |
| Maruyama, S | 1 |
| Matsuo, S | 1 |
| Nakao, M | 1 |
| Tsuchiya, T | 1 |
| Teramachi, H | 1 |
| Abdel-Rahman, O | 2 |
| ElHalawani, H | 2 |
| Essam-Eldin, S | 2 |
| Yamamoto, K | 1 |
| Suzuki, S | 2 |
| Ikegawa, K | 1 |
| Nomura, H | 2 |
| Fuse, N | 1 |
| Saito, S | 1 |
| Maeda, M | 1 |
| Saito, Y | 1 |
| Makino, Y | 1 |
| Iwase, H | 1 |
| Hayashi, Y | 1 |
| Yamada, R | 1 |
| Sotozono, C | 1 |
| Nakamura, T | 1 |
| Nishida, A | 1 |
| Nakanishi, S | 1 |
| Hirabatake, M | 1 |
| Tsuji, A | 1 |
| Kurimoto, Y | 1 |
| Kwakman, JJM | 1 |
| Baars, A | 1 |
| Boot, H | 1 |
| Pruijt, JFM | 1 |
| Winther, SB | 1 |
| Pfeiffer, P | 1 |
| Punt, CJA | 1 |
| Kojima, T | 1 |
| Matsui, T | 1 |
| Uemura, T | 1 |
| Fujimitsu, Y | 1 |
| Kure, N | 1 |
| Mochizuki, Y | 1 |
| Kojima, H | 1 |
| Shirasaka, T | 6 |
| Ichikawa, W | 2 |
| Yamamoto, W | 2 |
| Endo, H | 2 |
| Nagashima, F | 3 |
| Tanaka, R | 2 |
| Miya, T | 2 |
| Araki, K | 2 |
| Kodama, K | 2 |
| Sunakawa, Y | 3 |
| Narabayashi, M | 2 |
| Miwa, K | 3 |
| Akiyama, Y | 2 |
| Kawara, K | 2 |
| Saif, MW | 2 |
| Syrigos, KN | 1 |
| Katirtzoglou, NA | 1 |
| Nakao, K | 1 |
| Ishii, Y | 1 |
| Takahashi, Y | 1 |
| Takayama, T | 1 |
| Asai, S | 1 |
| Matsumoto, Y | 1 |
| Dogru, M | 1 |
| Sato, EA | 1 |
| Ibrahim, OM | 1 |
| Tatematsu, Y | 1 |
| Ogawa, Y | 1 |
| Tsubota, K | 1 |
| Hirose, T | 1 |
| Nishimura, K | 1 |
| Ishida, H | 1 |
| Yamashita, K | 1 |
| Mizuno, K | 1 |
| Adachi, M | 1 |
| Kihara, K | 1 |
| Kamimura, H | 1 |
| Isayama, H | 1 |
| Fujii, Y | 1 |
| Iino, Y | 1 |
| Shibahara, H | 1 |
| Kuze, S | 1 |
| Kyokane, T | 1 |
| Takamizawa, J | 1 |
| Nakamura, H | 1 |
| Atsumi, H | 1 |
| Fukushima, M | 3 |
| Sakamoto, K | 1 |
| Sakata, M | 1 |
| Nakagawa, F | 1 |
| Saito, H | 1 |
| Sakata, Y | 1 |
| Chuah, B | 1 |
| Goh, BC | 1 |
| Lee, SC | 1 |
| Soong, R | 1 |
| Lau, F | 1 |
| Mulay, M | 1 |
| Dinolfo, M | 1 |
| Lim, SE | 1 |
| Soo, R | 1 |
| Furuie, T | 1 |
| Saito, K | 4 |
| Zergebel, C | 4 |
| Rosen, LS | 2 |
| Zohar, S | 1 |
| Katsahian, S | 1 |
| O'Quigley, J | 1 |
| Kitamura, H | 1 |
| Miyanaga, T | 1 |
| Shin, H | 1 |
| Fujita, M | 1 |
| Miyazaki, M | 1 |
| Yagi, D | 1 |
| Ito, H | 1 |
| Asaumi, Y | 1 |
| Hirano, Y | 1 |
| Hayashida, Y | 1 |
| Maeda, K | 1 |
| Ota, K | 2 |
| Hayashi, H | 1 |
| Douden, K | 1 |
| Hattori, M | 1 |
| Hashidume, Y | 1 |
| Ravage-Mass, L | 1 |
| Mendelson, DS | 1 |
| Nakamura, K | 1 |
| Abu Lila, AS | 1 |
| Matsunaga, M | 1 |
| Doi, Y | 1 |
| Ishida, T | 1 |
| Kiwada, H | 1 |
| Chung, KY | 1 |
| Hollywood, E | 1 |
| Segal, M | 1 |
| Saltz, LB | 1 |
| Scheulen, ME | 1 |
| Hilger, RA | 1 |
| Mende, B | 1 |
| Strumberg, D | 1 |
| Miura, K | 1 |
| Yamaue, H | 1 |
| Sasaki, I | 1 |
| Hirashima, Y | 1 |
| Shirao, K | 1 |
| Zhuang, ZX | 1 |
| Zhu, H | 1 |
| Wang, J | 1 |
| Zhu, MG | 1 |
| Wang, H | 1 |
| Pu, WY | 1 |
| Bian, HH | 1 |
| Chen, L | 1 |
| Zhang, H | 1 |
| Cohen, SJ | 1 |
| Leichman, CG | 1 |
| Yeslow, G | 1 |
| Beard, M | 1 |
| Proefrock, A | 1 |
| Roedig, B | 1 |
| Damle, B | 1 |
| Letrent, SP | 1 |
| DeCillis, AP | 1 |
| Meropol, NJ | 1 |
| Sugimura, T | 1 |
| Peters, GJ | 3 |
| Noordhuis, P | 3 |
| Van Kuilenburg, AB | 1 |
| Schornagel, JH | 3 |
| Gall, H | 2 |
| Turner, SL | 2 |
| Swart, MS | 2 |
| Voorn, D | 2 |
| Van Gennip, AH | 1 |
| Wanders, J | 1 |
| Holwerda, U | 2 |
| Smid, K | 1 |
| Giaccone, G | 3 |
| Fumoleau, P | 2 |
| Van Groeningen, CJ | 3 |
| Schrijvers, A | 1 |
| Beijnen, JH | 1 |
| Schellens, JH | 1 |
| Rustum, YM | 1 |
| Hamuro, J | 1 |
| Taguchi, T | 5 |
| Hirata, K | 2 |
| Horikoshi, N | 2 |
| Tominaga, K | 1 |
| Sohma, K | 1 |
| Yamaguchi, K | 1 |
| Okazaki, M | 2 |
| Furuhata, T | 1 |
| Sasaki, K | 2 |
| Nakano, Y | 2 |
| Ishizuka, H | 2 |
| Yamada, Y | 2 |
| Uno, S | 2 |
| Yamamitsu, S | 1 |
| Endo, S | 1 |
| Kamataki, T | 1 |
| Morimoto, S | 1 |
| Kitada, N | 1 |
| Anami, S | 1 |
| Miyabe, T | 1 |
| Morita, S | 1 |
| Watari, M | 1 |
| Yamasaki, H | 1 |
| Imamura, H | 1 |
| Furukawa, H | 1 |
| Hasegawa, K | 2 |
| Tabuse, K | 1 |
| Murakami, Y | 1 |
| Aiba, K | 2 |
| Inuyama, Y | 1 |
| Kanamaru, R | 1 |
| Akazawa, S | 1 |
| Niitani, H | 1 |
| Furue, H | 1 |
| Kurihara, M | 1 |
| Suga, S | 1 |
| Ariyoshi, Y | 1 |
| Takai, S | 1 |
| Shimoyama, T | 1 |
| Toge, T | 1 |
| Takashima, S | 1 |
| Sugimachi, K | 1 |
| Hara, Y | 1 |
| Fujita, H | 1 |
| Kimura, K | 1 |
| Saito, T | 1 |
| Tsukagoshi, S | 1 |
| Nakao, I | 1 |
| Denno, R | 1 |
| de Vries, MJ | 1 |
| Pinedo, HM | 1 |
| Hanauske, AR | 1 |
| Hoff, PM | 2 |
| Wada, H | 1 |
| Saad, ED | 1 |
| Kubota, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced Non-squamous Non-small Cell Lung Cancer[NCT03700333] | Phase 3 | 120 participants (Anticipated) | Interventional | 2018-10-20 | Not yet recruiting | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for oxonic acid and Benign Neoplasms
| Article | Year |
|---|---|
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationsh | 2014 |
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I | 2016 |
S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2016 |
S-1: a promising new oral fluoropyrimidine derivative.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 2009 |
S-1 as a core anticancer fluoropyrimidine agent.
Topics: Absorption; Administration, Oral; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administra | 2012 |
[The principles of cancer treatment--changes in chemotherapy].
Topics: ADP Ribose Transferases; Animals; Antineoplastic Agents; Benzamides; Cisplatin; Drug Combinations; F | 2002 |
Thymidylate synthase: a critical target in cancer therapy?
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Proliferation; Clinical Tr | 2004 |
[Anticancer immunotherapy with perorally effective lentinan].
Topics: Adjuvants, Immunologic; Administration, Oral; Antineoplastic Agents; beta-Glucans; Drug Combinations | 2005 |
[Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinatio | 2006 |
[Pharmacokinetics of S-1].
Topics: Administration, Oral; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2006 |
[Development of fluorinated pyrimidines in Japan].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorode | 1993 |
The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2000 |
Other fluorinated pyrimidines in the treatment of solid tumors.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; | 2001 |
[5-fluorouracil and dihydropyrimidine dehydrogenase].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2001 |
14 trials available for oxonic acid and Benign Neoplasms
| Article | Year |
|---|---|
Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; | 2021 |
Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Bo | 2009 |
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2010 |
A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dihydrouracil Dehyd | 2011 |
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2011 |
Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biological Av | 2012 |
Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cross-Ov | 2013 |
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2002 |
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Dose-Respon | 2003 |
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2004 |
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Asia | 2008 |
[Phase I study of S-1. S-1 Study Group].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1997 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Drug Combinati | 1999 |
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Human | 2000 |
27 other studies available for oxonic acid and Benign Neoplasms
| Article | Year |
|---|---|
Incidence of Ophthalmic Disorders in Patients Treated with the Antineoplastic Agent S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Eye Diseases; Female; Humans; Incidence; M | 2017 |
[A Retrospective Investigation of Lacrimation in Patients Treated with S-1].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; | 2018 |
Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chromatograph | 2018 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2019 |
[Corneal epithelial disorder, lacrimal drainage obstruction, and conjunctivitis].
Topics: Antimetabolites, Antineoplastic; Conjunctivitis; Corneal Diseases; Drug Combinations; Epithelial Cel | 2015 |
Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carbop | 2015 |
[Evaluation of Drug Interaction between S-1 and Warfarin].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Drug Combinations; Drug In | 2016 |
[The Importance of Medication History Management by Hospital and Community Pharmacists for Oral Anticancer Drug S-1(Tegafur/Gimeracil/Oteracil Potassium)--A Retrospective Study].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Community Pha | 2016 |
Predictive factors for ocular complications caused by anticancer drug S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Conjunctivitis; Corneal Diseases; D | 2016 |
Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Denmark; Drug Combinations; Drug Substitution; Female; | 2017 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Mo | 2008 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
[Discussion of alleviating digestive medication toxicity in S-1 administered patients--retrospective and comparative study of the health records of continuously-administered patients and withdrawal patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Digestive System Diseases; Drug Combinations; Humans | 2009 |
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon H | 2010 |
S-1 induces meibomian gland dysfunction.
Topics: Aged; Antimetabolites, Antineoplastic; Corneal Diseases; Drug Combinations; Dry Eye Syndromes; Eyeli | 2010 |
[Suppression of renin-angiotensin system and cancer therapy (discussion)].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; B | 2010 |
[Optic lesions in patients with epiphora during S-1 therapy].
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Eye Diseases; Female; Humans; Lacrimal Apparatus | 2010 |
Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy | 2010 |
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asia, | 2011 |
An approach to meta-analysis of dose-finding studies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Computer S | 2011 |
[Investigation of epiphora following S-1 therapy].
Topics: Aged; Drug Combinations; Female; Humans; Lacrimal Apparatus Diseases; Male; Middle Aged; Neoplasms; | 2011 |
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Combined Modality Therap | 2011 |
[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Human | 2012 |
[Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
[Determining S-1 dosage at hospitals prioritizing cancer chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relat | 2008 |
[Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo].
Topics: Animals; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, | 1996 |
[Oral chemotherapeutic agents: the roles in cancer chemotherapy].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Co | 1999 |